hydroxocobalamin

Trade name: cyanokit

Small moleculeapproved

Approved

Apr 18, 1975

Hydroxocobalamin (also hydroxycobalamin, OHCbl) is a natural form, or vitamer, of vitamin B12. It is a member of the cobalamin family of compounds. Hydroxocobalamin, the active ingredient in Cyanokit, is cobinamide dihydroxide dihydrogen phosphate (ester), mono (inner salt), 3’-ester with 5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole. The drug substance is the hydroxylated active form of vitamin B12 and is a large molecule in which a trivalent cobalt ion is coordinated in four positions by a tetrapyrol (or corrin) ring. It is a hygroscopic, odorless, dark red, crystalline powder that is freely soluble in water and ethanol, and practically insoluble in acetone and diethyl ether. Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. Cyanide is an extremely toxic poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular hypoxia and metabolic acidosis. In massive acute cyanide poisoning, the mechanism of toxicity may involve other enzyme systems as well. Signs and symptoms of acute systemic cyanide poisoning may develop rapidly within minutes, depending on the route and extent of cyanide exposure. The action of Cyanokit is based on its ability to bind cyanide ions. Each hydroxocobalamin molecule can bind one cyanide ion by substituting it for the hydroxo ligand linked to the trivalent cobalt ion, to form cyanocobalamin, which is then excreted in the urine. — NCATS

Clinical trial activity

28 trials · 36 clinical orgs · 7 marketing orgs

Phase 1
0
Phase 2
9
Phase 3
6
Phase 4
6

Earliest trial started Nov 1, 1998 (NCT00097669)

Timeline

1970s

  1. Apr 18, 1975

    Merck — Earliest FDA Approval

  2. Apr 18, 1975

    Merck — NDA Organization

  3. Apr 18, 1975

    Merck — Marketing Organization

  4. Aug 16, 1978

    Actavis — Marketing Organization

1980s

  1. May 1, 1981

    Belmar Pharmacy — Marketing Organization

  2. Jun 15, 1982

    Abraxis — Marketing Organization

2000s

  1. Dec 15, 2006

    Serb SA — NDA Secondary Org

  2. Dec 15, 2006

    BTG — Marketing Organization

  3. Dec 15, 2006

    BTG — NDA Secondary Org

  4. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

  5. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • CyanideSEQUESTERING AGENT

    Cyanide sequestering agent

Approval history

  • approvedApr 18, 1975

Chemistry & pharmacology

Loading structure…

SMILES

[OH-].[Co+3].C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2[N-]C1=C(C)C3=NC(=CC4=NC(=C(C)C5=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)C(C)(C)[C@@H]3CCC(N)=O)OP([O-])(=O)O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)N7C=NC8=C7C=C(C)C(C)=C8
Mol. weight
1346.3551 g/mol
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • acetatocobalamin
  • alpharedisol
  • alpharedisol
  • berocca
  • cobalin-h
  • cobalin-h
  • cyanokit
  • cyanokit
  • cyanokit
  • cyanokit
  • hepavit
  • hydrocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin
  • hydroxocobalamin acetate
  • hydroxocobalamin acetate
  • hydroxocobalamin acetate
  • hydroxocobalamin acetate
  • hydroxocobalamin acetate
  • hydroxocobalamin anhydrous
  • hydroxocobalamin anhydrous
  • hydroxocobalamine
  • hydroxocobalamine
  • hydroxocobalamine
  • hydroxocobalaminum anhydrous
  • hydroxocobalaminum anhydrous
  • hydroxocobemine
  • hydroxocobemine
  • hydroxocobemine
  • hydroxomin
  • hydroxomin
  • hydroxycobalamin
  • hydroxycobalamin
  • hydroxycobalamin
  • hydroxycobalamin
  • hydroxycobalamine
  • hydroxycobalamine acetate
  • hydroxy vitamin b12
  • megamilbedoce
  • neo-cytamen
  • neo-cytamen
  • oh-cbl
  • oh-cbl
  • vitamin b12
  • vitamin b12

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07163364Phase 3Aug 31, 2025Shijiazhuang Pharma Group (CSPC)
NCT05536596Phase 2/Phase 3 (Phase 3)Sep 30, 2022Universidad de los Andes, Universitat Internacional de Catalunya
NCT04627181Phase 4Nov 30, 2020Christian Medical College, Vellore, India
NCT04259060Phase 2Jun 30, 2020Harvard University
NCT06160219Phase 2/Phase 3 (Phase 3)Aug 28, 2019Ain Shams University
NCT04054999Phase 4Aug 12, 2019Mayo Clinic
NCT03783091Phase 2Jul 31, 2019Medical College of Wisconsin
NCT03735316Phase 2Apr 25, 2019Mayo Clinic
NCT03446599Phase 2Nov 30, 2018Dartmouth University
NCT03372447Phase 4Dec 27, 2017Universidad Autonoma de Nuevo Leon
NCT02795572Phase 2Jun 1, 2017University of Calgary
NCT03069313Phase 2Oct 19, 2015Texas Tech University
NCT02272842Phase 2/Phase 3 (Phase 3)Apr 20, 2015Tribhuvan University, Uni Health, Uni Research, Norway, University of Bergen
NCT02270749Phase 4Oct 1, 2014Rijnstate Hospital
NCT02832726N/AJan 1, 2014Aarhus University
NCT01690962N/ANov 1, 2012Physicians Committee for Responsible Medicine
NCT02457507Phase 4Aug 1, 2011Chinese University of Hong Kong
NCT01795131Phase 2/Phase 3 (Phase 3)Feb 1, 2010International Center for Diarrheal Disease Research
NCT01201005N/AJul 1, 2009University of Bergen
NCT00939718N/AApr 1, 2009Aga Khan University
Showing 20 of 28 trials
Page 1 / 2

Organizations

Research & Development (36)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of BergenAcademic/Hospital3322004
Chinese University of Hong KongAcademic/Hospital2212004
Harvard UniversityAcademic/Hospital2222008
Mayo ClinicAcademic/Hospital2222019
Aarhus UniversityAcademic/Hospital1112014
Aga Khan UniversityAcademic/Hospital1112009
Ain Shams UniversityAcademic/Hospital1112019
Ariston Pharmaceuticals, Inc.For profit1112007
Canisius-Wilhelmina HospitalAcademic/Hospital1012007
Christian Medical College, Vellore, IndiaAcademic/Hospital1112020
Dartmouth UniversityAcademic/Hospital1112018
Foundation to Promote Research into Functional Vitamin B12 Deficiency, Bergen, NorwayAcademic/Hospital1012004
International Center for Diarrheal Disease ResearchAcademic/Hospital1112010
Medical College of WisconsinAcademic/Hospital1112019
Medical Health Research Infrastructure Council, AustraliaGovernment1011998
National Center for Research Resources (NCRR)Government1012005
National Health and Medical Research Council, AustraliaGovernment1011998
National Heart Foundation, AustraliaGovernment1011998
Physicians Committee for Responsible MedicineAcademic/Hospital1112012
Rijnstate HospitalAcademic/Hospital1112014
36 organizations
Page 1 / 2

Marketing (10)

OrganizationOrg typeRelationshipDate
AbraxisFor profitMKTGJun 15, 1982
ActavisFor profitMKTGAug 16, 1978
ActavisFor profitSYNAug 16, 1978
BTGFor profitMKTGDec 15, 2006
BTGFor profitNDA2Dec 15, 2006
Belmar PharmacyFor profitMKTGMay 1, 1981
MerckFor profitNDAApr 18, 1975
MerckFor profitMKTGApr 18, 1975
Serb SAFor profitNDA2Dec 15, 2006
Watson PharmaceuticalsFor profitMKTG